Combo Therapy Helps Mice Survive Chemo Drug Damage Longer
Graded Preliminary — experiments in young mice with artificially induced damage and ten animals per group; natural aging and people were not studied.
Animal study. Findings may not carry over to people, which is why the grade is capped at Preliminary.
- Design
- Animal study
- Participants
- 10
- Duration
- —
- Funding
- Immorta Bio Inc.
In mice with liver damage, the immune therapy and stem cells together lowered liver values more than either treatment alone.
Aged cells that have stopped dividing release signaling molecules. These may hold back tissue repair. So researchers tested a combination in mice: an immune therapy aimed at such cells, plus stem cells meant to repair tissue. Together, the two improved liver blood values in damaged mice more than either treatment alone.
The team damaged young mice in two ways. Some received the liver poison carbon tetrachloride. Others received the cancer drug doxorubicin, which triggers faster aging. Groups of ten mice got nothing, the immune therapy SenoVax, the stem cells or both. With the combination, liver values fell by 58 to 62 percent, compared with 32 to 40 percent for single treatments. After doxorubicin, all untreated mice had died by day 30. With the combination, half were still alive on day 35.
The study does not mimic natural aging, because the damage was triggered artificially. Whether the aged cells actually disappeared was not measured. The work was paid for by Immorta Bio, a company whose management includes several of the authors.
Conflict of Interest Disclosure: Immorta Bio funded the study; several authors are company managers and shareholders, and one sits on its advisory board.
Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.
